WASHINGTON (Reuters) - French pharmaceutical giant Sanofi (PA:SASY) will pay more than $25 million to settle charges that its Kazakhstan and Middle East subsidiaries made corrupt payments to win business, the top U.S. securities regulator said on Tuesday.
Without admitting or denying the findings, the company agreed to pay $17.5 million in disgorgement, $2.7 million in prejudgment interest and a civil penalty of $5 million, the Securities and Exchange Commission said.